Pharmaceuticals

Sequoia Group launches 'Pages,' a collaborative workspace, and its 2026 report to help firms navigate rising costs, AI talent wars, and compensation.

With a top expert at the helm, AltaThera aims to expand its heart rhythm drug for kids, balancing life-saving potential with critical safety warnings.

US brands hit a record $6.44T value, led by tech titans. But as corporate power grows, America's global reputation is in a steep, historic decline.

The PBM is launching new solutions that challenge traditional pricing models with predictable costs and integrated patient support for obesity care.

Apimeds Pharmaceuticals accuses its Korean partner of an illegal board seizure, sparking a high-stakes legal fight in Delaware and Seoul over a broken merger.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

Cipla Health launches a Masala Guava flavored ORS, targeting India's daily wellness market by turning a medical staple into an enjoyable hydration choice.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

Merck's breakthrough PAH drug is now covered in several provinces, offering new hope. But what about its high cost and access for the rest of Canada?

Investors eye Cardinal Health's April 30 report for signs its aggressive diversification and specialty pharma push can sustain its powerful earnings momentum.

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

Wilmington PharmaTech is doubling its API capacity, a key move to bolster the U.S. drug supply chain and reduce reliance on foreign manufacturing.

Following a record year, Knight Therapeutics is doubling its share repurchase plan. We analyze the strategy, financials, and what it means for investors.

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

The life sciences analytics provider earned a top sustainability rating, signaling a shift where ESG performance is now critical for pharma partnerships.